Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Psychopharmacology (Berl). 2020 May 8;237(7):2201–2212. doi: 10.1007/s00213-020-05530-y

Figure 1: Drug effects on ICSS and body weight in the absence of IP acid.

Figure 1:

Horizontal axes: Time in days of treatment. Vertical axes: (Panels a-c) ICSS performance expressed as the % baseline number of pre-drug reinforcements earned per 10-min component; (Panels d-f) Body weight expressed as the % baseline weight. All points show mean±SEM for N=6 rats (3 male and 3 female) except for the vehicle, ketorolac, and nortriptyline groups (N=7 rats, 4 male and 3 female). Filled symbols in the bottom panels indicate points significantly different from “Vehicle” on a given treatment day as indicated by a significant Treatment × Day interaction or a main effect of Treatment in the two-way ANOVA followed by a Holm-Sidak post-hoc test. Because effects of each drug were compared to vehicle in separate two-way ANOVAs, the criterion for significance was adjusted for multiple comparisons to the vehicle group (p<0.0083 = 0.05 ÷ 6 different test drugs). Significant statistical results are as follows: For nortriptyline (Panel e), there was a main effect of Treatment [F(1,12)=11.570, p=0.005], for norBNI (Panel f), there was a significant Treatment × Day interaction [F(5,55)=3.834, p=0.005], for U69593 (Panel f), there was a significant Treatment × Day interaction [F(5,55)=5.670, p<0.001].